Line
Drug Stocks Against the Market
Twenty large U.S.-listed drugmakers (by market value) and the S&P 500, price indexed to the start of the window
Plays the chart through its history. Pauses are where the data set a record or moved most.
Drugmakers: the largest U.S.-listed companies in SEC industries 2834 and 2836, weighted by market value, so Eli Lilly carries the most weight. Novo Nordisk, AstraZeneca, Novartis, Sanofi and GSK file no U.S. share counts and are left out. Prices only. Calculated by Palanor from licensed daily closes.
Whether investors are paying up for the drug industry or marking it down, against the market as a whole. Patent expiries, U.S. drug-pricing rules, tariffs and the obesity-drug race all show up here first.
What this chart reads
- Large U.S.-Listed Drugmakers Indexas “Large drugmakers”latest 2026-10-22
- SPDR S&P 500 ETF (SPY)as “S&P 500 (SPY)”latest 2026-10-22
Sources
Large U.S.-Listed Drugmakers Index. Source: Daily closes through a licensed market data provider; share counts from SEC filings. Calculated by Palanor.
SPDR S&P 500 ETF (SPY). Source: End-of-day closing prices from a licensed market data provider; primary listing: NYSE Arca. Shown in Palanor; not redistributed through the API or MCP.
Charts are drawn from Palanor's signal library and recomputed from source data on every view. Transformations (changes, indexing, year-on-year rates) are Palanor's.